Healthcare -
Medical - Diagnostics & Research - NYSE - US
$ 180.62
-0.633 %
$ 129 B
Market Cap
34.14
P/E
1. INTRINSIC VALUE
Balance Sheet
Danaher Corporation
| Current Assets | 9.5 B |
| Cash & Short-Term Investments | 2.08 B |
| Receivables | 3.54 B |
| Other Current Assets | 3.88 B |
| Non-Current Assets | 68 B |
| Long-Term Investments | 0 |
| PP&E | 4.99 B |
| Other Non-Current Assets | 63.1 B |
| Current Liabilities | 6.8 B |
| Accounts Payable | 1.75 B |
| Short-Term Debt | 505 M |
| Other Current Liabilities | 4.54 B |
| Non-Current Liabilities | 21.2 B |
| Long-Term Debt | 15.5 B |
| Other Non-Current Liabilities | 5.69 B |
EFFICIENCY
Earnings Waterfall
Danaher Corporation
| Revenue | 23.9 B |
| Cost Of Revenue | 9.67 B |
| Gross Profit | 14.2 B |
| Operating Expenses | 9.34 B |
| Operating Income | 4.86 B |
| Other Expenses | 964 M |
| Net Income | 3.9 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Danaher Corporation
| Net Income | 3.9 B |
| Depreciation & Amortization | 2.35 B |
| Capital Expenditures | -1.39 B |
| Stock-Based Compensation | 288 M |
| Change in Working Capital | 266 M |
| Others | -348 M |
| Free Cash Flow | 5.3 B |
Wall Street Analysts Price Targets
Danaher Corporation
Wall Street analysts predict an average 1-year price target for DHR of $280 , with forecasts ranging from
a
low of
$250 to a high of $315 .
DHR Lowest Price Target
Wall Street Target
250 USD
38.41%
DHR Average Price Target
Wall Street Target
280 USD
54.84%
DHR Highest Price Target
Wall Street Target
315 USD
74.40%
4. DIVIDEND
ANALYSIS
0.12%
DIVIDEND YIELD
0.32 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Danaher Corporation
Sold
0-3 MONTHS
1.39 M USD 2
3-6 MONTHS
8.22 M USD 1
6-9 MONTHS
15 M USD 6
9-12 MONTHS
37.5 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds
DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.
zacks.com
- 2 weeks ago
3 Wide-Moat Dividend Stars For A Championship Portfolio
I linked investing to baseball, showing how consistency, like the A's Moneyball approach, wins long term. Steady dividend growers and low-volatility stocks outperform, especially in rocky markets. Top teams like the Dodgers now pair consistency with big spending. Similarly, investors need financially strong, wide-moat stocks with rising cash flow, durable dividends, and resilience. Moreover, I'm targeting stocks with these traits: reliable growth, low payout ratios, and recession-proof models. Like championship teams, they're built to win over time.
seekingalpha.com
- 2 weeks ago
Danaher Corporation: A Mixed Bag Of Strength And Stagnation
Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent. DHR doesn't offer much in terms of dividend yield, but its above-average dividend growth could be attractive for dividend investors.
seekingalpha.com
- 2 weeks ago
Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years.
seekingalpha.com
- 2 weeks ago
8 Upcoming Dividend Increases, Including A King
Highlighting eight companies with upcoming dividend increases, four exceeding 10%, and an average increase of 11.4%, median at 9%. My investment strategy focuses on buying, holding, and expanding stakes in companies with consistent dividend growth and benchmark-beating performance. The list is curated using data from the "U.S. Dividend Champions" spreadsheet and NASDAQ, ensuring a minimum of five years of dividend growth.
seekingalpha.com
- 3 weeks ago
Danaher: Near 5-Year Low Is A Great Entry Point
Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years.
seekingalpha.com
- 4 weeks ago
Danaher Schedules First Quarter 2025 Earnings Conference Call
WASHINGTON , March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour.
prnewswire.com
- 1 month ago
Here's Why You Should Avoid Betting on Danaher Stock Right Now
Persistent softness in the Life Sciences segment weighs on DHR's performance. An increase in operating expenses is an added concern.
zacks.com
- 1 month ago
Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System
The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif. , March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) clearance from the U.S. Food and Drug Administration.
prnewswire.com
- 1 month ago
Danaher Corporation (DHR) TD Cowen 45th Annual Health Care Conference Transcript
Danaher Corporation (NYSE:DHR ) TD Cowen 45th Annual Health Care Conference Call March 5, 2025 10:30 AM ET Company Participants Rainer Blair – President and Chief Executive Officer Conference Call Participants Dan Brennan – TD Cowen Dan Brennan Welcome to day-three of the TD Cowen Global Healthcare Conference. I'm Dan Brennan, I follow tools and diagnostics.
seekingalpha.com
- 1 month ago
Danaher to Present at TD Cowen Health Care Conference
WASHINGTON , Feb. 25, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Wednesday, March 5, 2025 at 10:30 a.m.
prnewswire.com
- 1 month ago
Danaher Rewards Shareholders With 18.5% Dividend Increase
DHR's measures to consistently reward shareholders through dividends and share buybacks hold promise.
zacks.com
- 1 month ago
8. Profile
Summary
Danaher Corporation DHR
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 129 B
Dividend Yield
0.12%
Description
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Contact
2200 Pennsylvania Avenue, NW, Washington, DC, 20037-1701
https://www.danaher.com
IPO
Date
Dec. 29, 1978
Employees
61000
Officers
Mr. Mitchell P. Rales
Co-Founder & Director
Mr. Brian W. Ellis J.D.
Senior Vice President, General Counsel & Chief Compliance Officer
Mr. Christopher M. Bouda
Vice President & Chief Accounting Officer
Mr. John Bedford
Vice President of Investor Relations
Mr. Matthew R. McGrew
Chief Financial Officer & Executive Vice President
Dr. Jose-Carlos Gutierrez-Ramos Ph.D.
Senior Vice President & Chief Science Officer
Ms. Georgeann F. Couchara
Senior Vice President of Human Resources
Mr. Rainer M. Blair
President, Chief Executive Officer & Director
Mr. Steven M. Rales
Co-Founder & Chairman
Mr. Daniel A. Raskas J.D.
Senior Vice President of Corporate Development